drugset / Trial / NCT05904457
A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer
Phase 2
Unknown
32 enrolled
Asan Medical Center
Boryung Pharmaceutical Co., Ltd · collabKorean Cancer Study Group · collab
NaSingle-groupOpen-labelTreatment
Summary
A national, prospective, multi-center, open-label, single arm phase II trial investigating the efficacy and safety of bevacizumab plus erlotinib in patients with advanced cancers which harbors genomic alterations in Krebs cycle
Timeline
- Start
- 2023-01-02
- Primary completion
- 2025-01-31
- Completion
- 2026-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |